Magle Chemoswed Holding AB (OSTO:MAGLE) Current Accrued Expense: kr Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MAGLE Magle Chemoswed Holding AB OSTO:MAGLE
39 GF Score
Price kr0.39
GF Value kr23.42
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Magle Chemoswed Holding AB Current Accrued Expense?

Magle Chemoswed Holding AB OSTO:MAGLE 39 Current Accrued Expense is kr Mil as of Jun. 2026. GuruFocus rates OSTO:MAGLE with a GF Score™ of 39/100 and a GF Value™ of kr23.42 (Possible Value Trap). The stock has 6 warning signs investors should review.

Magle Chemoswed Holding AB's Current Accrued Expense for the quarter that ended in Jun. 2026 was kr Mil.

Magle Chemoswed Holding AB's quarterly Current Accrued Expense declined from Dec. 2025 (kr28.2 Mil) to Mar. 2026 (kr Mil) but then stayed the same from Mar. 2026 (kr Mil) to Jun. 2026 (kr Mil).

Magle Chemoswed Holding AB's annual Current Accrued Expense increased from Dec. 2023 (kr5.2 Mil) to Dec. 2024 (kr29.3 Mil) but then declined from Dec. 2024 (kr29.3 Mil) to Dec. 2025 (kr28.2 Mil).

Magle Chemoswed Holding AB Current Accrued Expense Related Terms

Magle Chemoswed Holding AB Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Magle Chemoswed Holding AB's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Magle Chemoswed Holding AB Current Accrued Expense Chart

Magle Chemoswed Holding AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 5.65 4.94 5.16 29.26 28.23

Magle Chemoswed Holding AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 28.23 - -
OSTO:MAGLE
39GF Score
Magle Chemoswed Holding AB OSTO:MAGLE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Magle Chemoswed Holding AB Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr Mil mean?
Magle Chemoswed Holding AB (OSTO:MAGLE) has a Current Accrued Expense of kr Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Magle Chemoswed Holding AB and its competitors.
Is Magle Chemoswed Holding AB's Current Accrued Expense too high?
Magle Chemoswed Holding AB's current Current Accrued Expense is kr Mil. Overall, Magle Chemoswed Holding AB has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Magle Chemoswed Holding AB's Current Accrued Expense compare to VRTX and REGN?
Magle Chemoswed Holding AB's Current Accrued Expense of kr Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Magle Chemoswed Holding AB and its competitors. Magle Chemoswed Holding AB's current Current Accrued Expense is kr Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Magle Chemoswed Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB (OSTO:MAGLE) is currently considered Possible Value Trap. The stock's GF Value™ is kr23.42, compared to a current price of kr0.39 — trading 98.3% below its estimated fair value. The current Current Accrued Expense is kr Mil. Magle Chemoswed Holding AB's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Magle Chemoswed Holding AB (OSTO:MAGLE), the current Current Accrued Expense is kr Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Magle Chemoswed Holding AB (OSTO:MAGLE) Overvalued in 2026?

Based on GuruFocus' analysis, Magle Chemoswed Holding AB stock appears to be undervalued. The current stock price of kr0.39 is trading 98.3% below its estimated GF Value™ of kr23.42. GuruFocus considers Magle Chemoswed Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:MAGLE:

  • Current Accrued Expense: kr Mil
  • GF Value™: kr23.42 vs. price of kr0.39 (98.3% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the OSTO:MAGLE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Magle Chemoswed Holding AB Business Description

Other Exchanges 52X:Germany
Address Agneslundsvagen 27, Malmo, SWE, 21215
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
39GF Score

Get the complete analysis for OSTO:MAGLE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.39
Price
kr23.42
GF Value